<DOC>
	<DOCNO>NCT02178098</DOCNO>
	<brief_summary>This Phase 2 study ass efficacy safety ETC-1002 monotherapy versus placebo patient hypercholesterolemia hypertension .</brief_summary>
	<brief_title>Evaluation ETC-1002 Patients With Hypercholesterolemia Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Mean 24hour ambulatory SBP great equal 130 mmHg Mean 24hour ambulatory DBP great equal 80 mmHg Fasting LDLC 100 220 mg/dL Fasting triglycerides less 400 mg/dL Body mass index ( BMI ) 18 45 kg/m2 Known suspected secondary hypertension history malignant hypertension Taking two antihypertension medication first visit History current clinically significant cardiovascular disease History current type 1 diabetes type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
</DOC>